Center For Inherited Blood Disorders

What Center For Inherited Blood Disorders does

Center for Inherited Blood Disorders (CIBD) is a 501(c)(3) non-profit organization founded in 2009 and headquartered in Orange, California. It operates the only licensed freestanding clinic in California specializing in inherited bleeding and clotting disorders, serving children and adults through a multidisciplinary care model that integrates hematology, pharmacy, infusion, physical therapy, social work, psychology, and diagnostic laboratory services. CIBD treats patients with hemophilia A and B, von Willebrand disease, sickle cell disease, thalassemia, platelet disorders, thrombosis, and rare bleeding disorders, including specialized women's health clinics (SWAG+ and GEMM) addressing historically underserved female patients.

CIBD's core clinical platform is anchored by four integrated units: a Clinic providing diagnosis and lifelong management; an on-site Infusion Center delivering gene therapy, iron infusions, biologics, and specialty medications (expanded in January 2026 beyond blood disorders to include anemia, autoimmune conditions, and thrombocytopenia); a Pharmacy participating in the HRSA 340B Drug Pricing Program, which enables purchase of clotting factor and other medications at reduced cost with savings reinvested into patient services; and the Hemophilia and Allied Bleeding Disorders Laboratory (HADL) performing diagnostic testing. Its technology stack includes musculoskeletal ultrasound (MSKUS) for real-time bleed detection, EPIC EHR with MyChart patient portal (launching August 25, 2026), and telehealth consultations. The organization delivered the first FDA-approved gene therapy infusion for Hemophilia A in the United States outside a clinical trial in December 2023 and has completed six gene therapy infusions across two FDA-approved products as of January 2026.

CIBD's revenue model blends professional services reimbursement (clinical care billed to insurance including Medi-Cal, California Children's Services, GHPP, and Covered California), the 340B pharmacy program (drug margin capture reinvested in care), and federal grants from the CDC and HRSA. The organization also serves as the Regional Core Center for the Western States Regional Hemophilia Network (WSRHN/Region IX), providing programmatic, fiscal, and clinical direction to 13 Hemophilia Treatment Centers across California, Guam, Hawaii, and Nevada, a network that served over 7,200 patients and conducted over 3,100 diagnostic tests in 2021. Strategic hospital and university affiliations include CHOC, Providence St. Joseph of Orange, UC Irvine, UCSF, Stanford, CHLA, and UC Davis.

Name

Center For Inherited Blood Disorders

Legal name

Center for Inherited Blood Disorders

Website

https://cibd-ca.org

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Center for Inherited Blood Disorders (CIBD) is a 501(c)(3) non-profit operating the only licensed freestanding bleeding disorder clinic in California, delivering multidisciplinary care to children and adults with inherited blood disorders and serving as the Regional Core Center for 13 HTCs across the western U.S.

Ownership category

akta.pro rank

Product category

Specialty Hematology / Hemophilia Treatment Center

NAICS

Blood and Organ Banks (621991)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Transfusion Medicine & Immunohematology (Blood Bank) (HLAFAMAG)

akta.pro secondary industry

Blood Bank/Transfusion Medicine LIS (HLACAMAE)

Keywords

• Hemophilia treatment services
• Bleeding disorders care
• Sickle cell disease care
• Specialty hematology clinic
• Infusion therapy services

Headquarters

HQ city

Orange

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. 340B Pharmacy Program: CIBD participates in the HRSA 340B Drug Pricing Program, purchasing outpatient medications at reduced prices for patients with bleeding disorders. Savings from discounted drug purchases are reinvested into providing comprehensive care services including care coordination, patient education, social services, mental health support, and financial assistance.
2. Clinical Services Revenue: Reimbursement for clinical services including hematology consultations, infusion therapy, physical therapy, social work, and diagnostic laboratory services. Reimbursement varies and may not fully cover the true cost of HTC care, with CDC and HRSA grants providing partial support for surveillance and access goals.
3. Federal Grants (CDC/HRSA): CIBD receives partial federal support through CDC and HRSA grants as part of the national HTC network. These grants support bleeding disorders surveillance, HIV risk reduction services, and ensuring access to care, though they do not fully cover comprehensive care costs.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

CIBD is a nonprofit Hemophilia Treatment Center providing comprehensive, multidisciplinary clinical care for children and adults with inherited blood disorders including Hemophilia A and B, Von Willebrand Disease, Sickle Cell Disease, Thalassemia, platelet disorders, thrombosis, and rare bleeding disorders. The integrated offering combines hematology consultations, an on-site infusion center for IV therapies including FDA-approved gene therapy, a 340B-discounted pharmacy, a diagnostic laboratory, physical therapy, social work, psychological counseling, and women's health clinics (SWAG+ and GEMM). As Regional Core Center for WSRHN/Region IX, CIBD also coordinates programmatic direction and grants management across 13 HTCs.

Product overview

CIBD operates as a single freestanding specialty clinic in California providing comprehensive, multidisciplinary care for patients with inherited blood disorders. The core offering is integrated Clinic Services supported by an on-site Infusion Center, Pharmacy (with 340B Program), and Diagnostics Laboratory. Patient access is facilitated through a Patient Portal (Triarq Clouds, transitioning to MyChart/EPIC in August 2026). Specialized programs include women's health clinics (SWAG+ and GEMM), psychological counseling, physical therapy with musculoskeletal ultrasound, social work services, teen transition programs, and a gene therapy program offering FDA-approved treatments. As regional core center for the Western States Regional Hemophilia Network, CIBD also coordinates care across 13 Hemophilia Treatment Centers.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinic Services Comprehensive multidisciplinary medical care for children and adults with Hemophilia A and B, Von Willebrand Disease, Sickle Cell Disease, Thalassemia, platelet disorders, thrombosis, rare bleeding disorders, and anemias. Delivered by a team of board-certified hematologists, nurses, physical therapists, social workers, psychologists, and pharmacists providing diagnosis, treatment, prevention, education, and lifelong management.
• Infusion Center On-site infusion center providing convenient administration of IV medications including FDA-approved gene therapy for Hemophilia A and B, mast cell infusion, iron infusion, biologics, and IVIG. Expanded in 2026 to serve adult and pediatric patients with anemia, autoimmune disorders, and thrombocytopenia in addition to inherited blood disorder patients.
• Pharmacy Services State-of-the-art clinical pharmacy purchasing medical supplies, clotting factors, and prescription medications at discounted rates through the HRSA 340B Drug Pricing Program. Savings are passed directly to patients with inherited bleeding disorders, lowering the cost barrier to factor therapy and supportive medications.
• Diagnostics Laboratory (HADL) Hemophilia and Allied Bleeding Disorders Laboratory (HADL) providing specialized diagnostic testing for residents with suspected inherited blood disorders. Processes more than 3,100 diagnostic tests annually for the WSRHN/Region IX network across California, Hawaii, Nevada, and Guam.
• Research & Special Projects Clinical trials program including gene therapy trials, and quality improvement projects aimed at improving access to and quality of care for patients with bleeding and clotting disorders. Includes participation in ATHN DataSet, CDC Community Counts surveillance, and patient satisfaction benchmarking.
• SWAG+ Clinic (Space for Women & Girls+) Specialized women's health clinic focused on adolescents and individuals who menstruate, addressing the unique impacts of bleeding disorders on menstrual and reproductive health.
• GEMM Clinic (Gynecology Evaluation for Menses & Maternity) Specialized women's health clinic for adult women navigating complex menstrual and reproductive health concerns related to blood disorders, operated in collaboration with CHOC Adolescent Medicine and UCI OB/GYN.
• Patient Portal (Triarq Clouds) Current secure online patient portal providing patients with appointment management, access to health records, communication with care providers, and care coordination.
• MyChart Patient Portal Upcoming secure patient portal integrated with EPIC electronic health record system, providing patients with simplified management of appointments, health records, and communication with care providers.
• Western States Regional Hemophilia Network (WSRHN) Coordination Regional network coordination providing programmatic and fiscal direction, grants management, capacity building, clinical education, technical assistance, evaluation, and policy guidance for 13 Hemophilia Treatment Centers serving more than 7,200 patients across California, Guam, Hawaii, and Nevada.
• Gene Therapy Program Advanced gene therapy program offering FDA-approved gene therapies for Hemophilia A and Hemophilia B administered through CIBD's on-site infusion center. Includes the first FDA-approved Hemophilia A gene therapy delivered outside a clinical trial in the US.

Quantifiable outcome

• 40% reduction in mortality for hemophilia patients treated at HTCs
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature4 records

Partnerships

Twelve partnerships are on record, tiered core, major and minor.

• Western States Regional Hemophilia Network (WSRHN/Region IX)coreStrategic or Co-development PartnerCIBD serves as the Regional Core Center for the Western States Regional Hemophilia Network, representing 13 HTCs in California, Guam, Hawaii, and Nevada. CIBD provides programmatic and fiscal direction, grants management, capacity building, clinical education, technical assistance, evaluation, and policy guidance. The network served over 7,200 patients in 2021.
• Centers for Disease Control and Prevention (CDC)coreStrategic or Co-development PartnerCDC provides partial support for HTCs and funds bleeding disorders surveillance through initiatives including Community Counts. CDC goals include monitoring health and ensuring access to care for people with bleeding and clotting disorders.
• Health Resources and Services Administration (HRSA)coreStrategic or Co-development PartnerHRSA provides federal support for the HTC network through the Maternal and Child Health Bureau. HRSA goals include monitoring health and ensuring access to care for people with bleeding and clotting disorders.
• Children's Hospital of Orange County (CHOC)majorStrategic or Co-development PartnerCHOC is a hospital affiliation partner providing access to pediatric hospital services, emergency care, and specialized pediatric care for CIBD patients when hospitalization is needed.
• Providence St. Joseph Hospital of OrangemajorStrategic or Co-development PartnerHospital affiliation partner providing access to adult medical and surgical services for CIBD patients when hospitalization is needed.
• UC Irvine Medical CentermajorStrategic or Co-development PartnerUniversity affiliation partner providing access to academic medical center services and potential clinical trial opportunities for CIBD patients.
• American Thrombosis and Hemostasis Network (ATHN)majorTechnology or IntegrationATHN sponsors the Hemostasis and Thrombosis Data Set used by HTCs to support research. CIBD participates in ATHN projects and research studies.
• National Hemophilia FoundationmajorStrategic or Co-development PartnerNHF provides clinical guidelines, standards of care (MASAC documents), professional education, and advocacy for the bleeding disorders community. CIBD follows NHF recommendations for care.
• Hemophilia Foundation of Southern CaliforniamajorGTM or Marketing PartnerLocal chapter providing patient education, support programs, emergency financial assistance, scholarships, and community events including the Unite for Bleeding Disorders Walk.
• Sickle Cell Disease Foundation of CaliforniaminorGTM or Marketing PartnerCommunity organization providing education, peer support, and advocacy for patients with sickle cell disease.
• Painted Turtle CampminorGTM or Marketing PartnerSummer camp program for children with bleeding disorders, providing recreational and peer support opportunities. CIBD facilitates camp registrations and referrals.
• YETI (Youth Effectively Transitioning to Independence)minorGTM or Marketing PartnerTeen leadership retreat program helping teens with bleeding disorders build confidence and leadership skills during transition to young adulthood.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• UCSF Hemophilia Treatment Center: Federally funded HTC serving pediatric and adult hemophilia patients in Northern California. Directly comparable as a regional HTC providing comprehensive multidisciplinary care, factor therapy, gene therapy administration, and 340B pharmacy services within the WSRHN network alongside CIBD.
• Stanford Hemophilia Treatment Center: Pediatric and adult HTC within Stanford Children's Health, providing comprehensive care for bleeding and clotting disorders. Comparable as a WSRHN network member with overlapping clinical services, 340B pharmacy, and participation in ATHN data initiatives.
• Children's Hospital Los Angeles (CHLA) HTC: Pediatric HTC within CHLA providing comprehensive hematology care for inherited blood disorders in Southern California. Comparable in clinical model and WSRHN participation, though hospital-embedded rather than freestanding.
• UC Davis Hemophilia Treatment Center: Regional HTC within UC Davis Health providing multidisciplinary bleeding disorders care. Comparable as a WSRHN member offering infusion services, factor therapy, and comprehensive clinical care with 340B pharmacy.
• UC San Diego Hemophilia Treatment Center: Regional HTC at UC San Diego Health serving Southern California patients with inherited bleeding and clotting disorders. Comparable in offering comprehensive care model, pharmacy services, and WSRHN participation.
• Rady Children's Hospital San Diego HTC: Pediatric HTC within Rady Children's Hospital serving Southern California. Comparable in clinical model for pediatric inherited blood disorders care, with active WSRHN network participation.
• Orthopaedic Institute for Children (UCLA-affiliated): Specialty pediatric orthopedic provider in Los Angeles with HTC services for hemophilia and bleeding disorder patients. Comparable as a WSRHN-affiliated provider treating musculoskeletal complications of inherited blood disorders.

Others

• American Thrombosis and Hemostasis Network (ATHN): National nonprofit supporting the HTC network through data infrastructure (ATHN DataSet), research coordination, and quality initiatives. Adjacent/ecosystem peer given CIBD's participation in ATHN-sponsored projects and the network's role as enabling infrastructure for HTCs.
• National Hemophilia Foundation (NHF): National patient advocacy organization setting MASAC clinical guidelines and standards for bleeding disorders care. Comparable community/ecosystem role given CIBD's adherence to NHF guidelines and partnership in community programs, though focused on advocacy rather than direct clinical care.
• Hemophilia Foundation of Southern California: Local chapter providing patient education, support programs, and community events (Unite for Bleeding Disorders Walk) for the Southern California bleeding disorders community. Ecosystem peer working alongside CIBD on patient outreach and community engagement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights7 records

Customer concentration

• Facebookfacebook.com/people/Center-for-Inherited-Blood-Disorders-CIBD/61582983218479
• LinkedInlinkedin.com/company/center-for-comprehensive-care-and-diagnosis-of-inherited-blood-disorders-cibd-
• Instagraminstagram.com/cibd.ca

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Center For Inherited Blood Disorders